Wealthfront Advisers LLC Invests $1 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Wealthfront Advisers LLC acquired a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 48,568 shares of the company's stock, valued at approximately $1,001,000. Wealthfront Advisers LLC owned 0.11% of Pacira BioSciences as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in PCRX. Pacer Advisors Inc. boosted its holdings in shares of Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company's stock worth $74,681,000 after acquiring an additional 2,799,434 shares during the period. BNP Paribas Financial Markets raised its position in shares of Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock valued at $5,955,000 after buying an additional 288,662 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of Pacira BioSciences in the third quarter valued at approximately $3,469,000. Empowered Funds LLC acquired a new stake in shares of Pacira BioSciences in the third quarter valued at approximately $3,286,000. Finally, Impax Asset Management Group plc raised its position in shares of Pacira BioSciences by 81.0% in the third quarter. Impax Asset Management Group plc now owns 470,603 shares of the company's stock valued at $7,083,000 after buying an additional 210,576 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Wall Street Analysts Forecast Growth

PCRX has been the subject of a number of analyst reports. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Barclays lifted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC boosted their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, HC Wainwright boosted their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a "buy" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Pacira BioSciences currently has a consensus rating of "Hold" and an average target price of $27.22.

Remove Ads

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded up $0.61 during trading on Wednesday, hitting $24.28. 494,891 shares of the company were exchanged, compared to its average volume of 893,418. The business's 50 day moving average is $24.15 and its 200-day moving average is $19.42. The company has a market capitalization of $1.12 billion, a P/E ratio of -11.96 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.